MALDI Imaging mass spectrometry: Current frontiers and perspectives in pathology research and practice

Laboratory Investigation

Volumn 95, Issue 4, 2015, Pages 422-431

  Aichler, Michaela ^a   Walch, Axel ^a  

^a INSTITUTE OF EPIDEMIOLOGY   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

LIPID; PROTEIN;

ARTICLE; CELL METABOLISM; DISEASE CLASSIFICATION; HUMAN; IMMUNOHISTOCHEMISTRY; LIQUID CHROMATOGRAPHY; MASS SPECTROMETRY; MATRIX ASSISTED LASER DESORPTION IONIZATION TIME OF FLIGHT MASS SPECTROMETRY; PATHOLOGY; PRIORITY JOURNAL; PROGNOSIS; TREATMENT RESPONSE; ANIMAL; HISTOLOGY; MEDICAL RESEARCH; MOLECULAR IMAGING; MOUSE; RAT;

ANIMALS; BIOMEDICAL RESEARCH; HISTOLOGICAL TECHNIQUES; HUMANS; MICE; MOLECULAR IMAGING; PATHOLOGY; RATS; SPECTROMETRY, MASS, MATRIX-ASSISTED LASER DESORPTION-IONIZATION;

EID: 84926339388     PISSN: 00236837     EISSN: 15300307     Source Type: Journal    
DOI: 10.1038/labinvest.2014.156     Document Type: Article

References (106)

1. Norris JL, Caprioli RM. Imaging mass spectrometry: a new tool for pathology in a molecular age. Proteomics Clin Appl 2013;7:733-738.
2. Norris JL, Caprioli RM. Analysis of tissue specimens by matrix-assisted laser desorption/ionization imaging mass spectrometry in biological and clinical research. Chem Rev 2013;113:2309-2342.
3. Caprioli RM, Farmer TB, Gile J. Molecular imaging of biological samples: localization of peptides and proteins using MALDI-TOF MS. Anal Chem 1997;69:4751-4760.
4. Stoeckli M, Chaurand P, Hallahan DE, et al. Imaging mass spectrometry: a new technology for the analysis of protein expression in mammalian tissues. Nat Med 2001;7:493-496.
5. Schwamborn K, Caprioli RM. Molecular imaging by mass spectrometry-looking beyond classical histology. Nat Rev Cancer 2010;10:639-646.
6. Karas M, Kruger R. Ion formation in MALDI: the cluster ionization mechanism. Chem Rev 2003;103:427-440.
7. Jaskolla TW, Karas M. Compelling evidence for Lucky Survivor and gas phase protonation: the unified MALDI analyte protonation mechanism. J Am Soc Mass Spectrom 2011;22:976-988.
8. Rompp A, Spengler B. Mass spectrometry imaging with high resolution in mass and space. Histochem Cell Biol 2013;139:759-783.
9. Rompp A, Guenther S, Schober Y, et al. Histology by mass spectrometry: label-free tissue characterization obtained from high-accuracy bioanalytical imaging. Angew Chem Int Ed Engl 2010;49:3834-3838.
10. Rompp A, Guenther S, Takats Z, et al. Mass spectrometry imaging with high resolution in mass and space (HR(2) MSI) for reliable investigation of drug compound distributions on the cellular level. Anal Bioanal Chem 2011;401:65-73.
11. Komatsu M, Murayama Y, Hashimoto H. Protein fragment imaging using ink jet printing digestion technique. Appl Surf Sci 2008;255: 1162-1164.
12. Chaurand P, Latham JC, Lane KB, et al. Imaging mass spectrometry of intact proteins from alcohol-preserved tissue specimens: bypassing formalin fixation. J Proteome Res 2008;7:3543-3555.
13. Cornett DS, Reyzer ML, Chaurand P, et al. MALDI imaging mass spectrometry: molecular snapshots of biochemical systems. Nat Methods 2007;4:828-833.
14. Franck J, Arafah K, Barnes A, et al. Improving tissue preparation for matrix-assisted laser desorption ionization mass spectrometry imaging. Part 1: using microspotting. Anal Chem 2009;81:8193-8202.
15. van Remoortere A, van Zeijl RJ, van den Oever N, et al. MALDI imaging and profiling MS of higher mass proteins from tissue. J Am Soc Mass Spectrom 2010;21:1922-1929.
16. Mainini V, Bovo G, Chinello C, et al. Detection of high molecular weight proteins by MALDI imaging mass spectrometry. Mol Biosyst 2013;9:1101-1107.
17. Emmert-Buck MR, Bonner RF, Smith PD, et al. Laser capture microdissection. Science 1996;274:998-1001.
18. Espina V, Heiby M, Pierobon M, et al. Laser capture microdissection technology. Expert Rev Mol Diagn 2007;7:647-657.
19. Sun N, Ly A, Meding S, et al. High-resolution metabolite imaging of light and dark treated retina using MALDI-FTICR mass spectrometry. Proteomics 2014;14:913-923.
20. Maier SK, Hahne H, Gholami AM, et al. Comprehensive identification of proteins from MALDI imaging. Mol Cell Proteomics 2013;12: 2901-2910.
21. McDonnell LA, Walch A, Stoeckli M, et al. MSiMass list: a public database of identifications for protein MALDI MS imaging. J Proteome Res 2014;13:1138-1142.
22. Pote N, Alexandrov T, Le Faouder J, et al. Imaging mass spectrometry reveals modified forms of histone H4 as new biomarkers of microvascular invasion in hepatocellular carcinomas. Hepatology 2013;58: 983-994.
23. Djidja MC, Claude E, Snel MF, et al. Novel molecular tumour classification using MALDI-mass spectrometry imaging of tissue micro-array. Anal Bioanal Chem 2010;397:587-601.
24. Groseclose MR, Massion PP, Chaurand P, et al. High-throughput proteomic analysis of formalin-fixed paraffin-embedded tissue microarrays using MALDI imaging mass spectrometry. Proteomics 2008;8:3715-3724.
25. Morita Y, Ikegami K, Goto-Inoue N, et al. Imaging mass spectrometry of gastric carcinoma in formalin-fixed paraffin-embedded tissue microarray. Cancer Sci 2010;101:267-273.
26. Quaas A, Bahar AS, von Loga K, et al. MALDI imaging on large-scale tissue microarrays identifies molecular features associated with tumour phenotype in oesophageal cancer. Histopathology 2013;63: 455-462.
27. Steurer S, Borkowski C, Odinga S, et al. MALDI mass spectrometric imaging based identification of clinically relevant signals in prostate cancer using large-scale tissue microarrays. Int J Cancer 2013;133: 920-928.
28. Steurer S, Seddiqi AS, Singer JM, et al. MALDI imaging on tissue microarrays identifies molecular features associated with renal cell cancer phenotype. Anticancer Res 2014;34:2255-2261.
29. Steurer S, Singer JM, Rink M, et al. MALDI imaging-based identification of prognostically relevant signals in bladder cancer using large-scale tissue microarrays. Urol Oncol 2014;32:1225-1233.
30. Aichler M, Elsner M, Ludyga N, et al. Clinical response to chemotherapy in oesophageal adenocarcinoma patients is linked to defects in mitochondria. J Pathol 2013;230:410-419.
31. Abrass CK. Cellular lipid metabolism and the role of lipids in progressive renal disease. Am J Nephrol 2004;24:46-53.
32. Lee CH, Olson P, Evans RM. Minireview: lipid metabolism, metabolic diseases, and peroxisome proliferator-activated receptors. Endocrinology 2003;144:2201-2207.
33. Paradisi G, Ianniello F, Tomei C, et al. Longitudinal changes of adiponectin, carbohydrate and lipid metabolism in pregnant women at high risk for gestational diabetes. Gynecol Endocrinol 2010;26: 539-545.
34. Santos CR, Schulze A. Lipid metabolism in cancer. FEBS J 2012;279: 2610-2623.
35. Sparvero LJ, Amoscato AA, Kochanek PM, et al. Mass-spectrometry based oxidative lipidomics and lipid imaging: applications in traumatic brain injury. J Neurochem 2010;115:1322-1336.
36. Jackson SN, Wang HY, Woods AS. In situ structural characterization of phosphatidylcholines in brain tissue using MALDI-MS/MS. J Am Soc Mass Spectrom 2005;16:2052-2056.
37. Benabdellah F, Yu H, Brunelle A, et al. MALDI reveals membrane lipid profile reversion in MDX mice. Neurobiol Dis 2009;36:252-258.
38. Thomas A, Charbonneau JL, Fournaise E, et al. Sublimation of new matrix candidates for high spatial resolution imaging mass spectrometry of lipids: enhanced information in both positive and negative polarities after 1,5-diaminonapthalene deposition. Anal Chem 2012;84:2048-2054.
39. Rujoi M, Estrada R, Yappert MC. In situ MALDI-TOF MS regional analysis of neutral phospholipids in lens tissue. Anal Chem 2004;76:1657-1663.
40. Rujoi M, Jin J, Borchman D, et al. Isolation and lipid characterization of cholesterol-enriched fractions in cortical and nuclear human lens fibers. Invest Ophthalmol Vis Sci 2003;44:1634-1642.
41. Yappert MC, Rujoi M, Borchman D, et al. Glycero-versus sphingophospholipids: correlations with human and non-human mammalian lens growth. Exp Eye Res 2003;76:725-734.
42. Benabdellah F, Seyer A, Quinton L, et al. Mass spectrometry imaging of rat brain sections: nanomolar sensitivity with MALDI versus nanometer resolution by TOF-SIMS. Anal Bioanal Chem 2010;396:151-162.
43. Touboul D, Halgand F, Brunelle A, et al. Tissue molecular ion imaging by gold cluster ion bombardment. Anal Chem 2004;76:1550-1559.
44. Astigarraga E, Barreda-Gomez G, Lombardero L, et al. Profiling and imaging of lipids on brain and liver tissue by matrix-assisted laser desorption/ ionization mass spectrometry using 2-mercaptobenzothiazole as a matrix. Anal Chem 2008;80:9105-9114.
45. Burnum KE, Cornett DS, Puolitaival SM, et al. Spatial and temporal alterations of phospholipids determined by mass spectrometry during mouse embryo implantation. J Lipid Res 2009;50:2290-2298.
46. Colsch B, Woods AS. Localization and imaging of sialylated glycosphingolipids in brain tissue sections by MALDI mass spectrometry. Glycobiology 2010;20:661-667.
47. Garrett TJ, Dawson WW. Lipid geographical analysis of the primate macula by imaging mass spectrometry. Methods Mol Biol 2009;579:247-260.
48. Hayasaka T, Goto-Inoue N, Zaima N, et al. Organ-specific distributions of lysophosphatidylcholine and triacylglycerol in mouse embryo. Lipids 2009;44:837-848.
49. Landgraf RR, Prieto Conaway MC, Garrett TJ, et al. Imaging of lipids in spinal cord using intermediate pressure matrix-assisted laser desorption-linear ion trap/Orbitrap MS. Anal Chem 2009;81: 8488-8495.
50. Meriaux C, Franck J, Wisztorski M, et al. Liquid ionic matrixes for MALDI mass spectrometry imaging of lipids. J Proteomics 2010;73:1204-1218.
51. Mikawa S, Suzuki M, Fujimoto C, et al. Imaging of phosphatidylcholines in the adult rat brain using MALDI-TOF MS. Neurosci Lett 2009;451:45-49.
52. Murphy RC, Hankin JA, Barkley RM. Imaging of lipid species by MALDI mass spectrometry. J Lipid Res 2009;50(Suppl):S317-S322.
53. Snel MF, Fuller M. High-spatial resolution matrix-assisted laser desorption ionization imaging analysis of glucosylceramide in spleen sections from a mouse model of Gaucher disease. Anal Chem 2010;82:3664-3670.
54. Sparvero LJ, Amoscato AA, Dixon CE, et al. Mapping of phospholipids by MALDI imaging (MALDI-MSI): realities and expectations. Chem Phys Lipids 2012;165:545-562.
55. Sugiura Y, Konishi Y, Zaima N, et al. Visualization of the cell-selective distribution of PUFA-containing phosphatidylcholines in mouse brain by imaging mass spectrometry. J Lipid Res 2009;50:1776-1788.
56. Vidova V, Pol J, Volny M, et al. Visualizing spatial lipid distribution in porcine lens by MALDI imaging high-resolution mass spectrometry. J Lipid Res 2010;51:2295-2302.
57. Wang X, Han J, Pan J, et al. Comprehensive imaging of porcine adrenal gland lipids by MALDI-FTMS using quercetin as a matrix. Anal Chem 2014;86:638-646.
58. Kurabe N, Hayasaka T, Ogawa M, et al. Accumulated phosphatidylcholine (16:0/16:1) in human colorectal cancer; possible involvement of LPCAT4. Cancer Sci 2013;104:1295-1302.
59. Miura D, Fujimura Y, Yamato M, et al. Ultrahighly sensitive in situ metabolomic imaging for visualizing spatiotemporal metabolic behaviors. Anal Chem 2010;82:9789-9796.
60. Hattori K, Kajimura M, Hishiki T, et al. Paradoxical ATP elevation in ischemic penumbra revealed by quantitative imaging mass spectrometry. Antioxid Redox Signal 2010;13:1157-1167.
61. Bao Y, Mukai K, Hishiki T, et al. Energy management by enhanced glycolysis in G1-phase in human colon cancer cells in vitro and in vivo. Mol Cancer Res 2013;11:973-985.
62. Nilsson A, Fehniger TE, Gustavsson L, et al. Fine mapping the spatial distribution and concentration of unlabeled drugs within tissue microcompartments using imaging mass spectrometry. PLoS One 2010; 5:e11411.
63. Morosi L, Spinelli P, Zucchetti M, et al. Determination of paclitaxel distribution in solid tumors by nano-particle assisted laser desorption ionization mass spectrometry imaging. PLoS One 2013; 8:e72532.
64. Pirman DA, Reich RF, Kiss A, et al. Quantitative MALDI tandem mass spectrometric imaging of cocaine from brain tissue with a deuterated internal standard. Anal Chem 2013;85:1081-1089.
65. Prideaux B, Stoeckli M. Mass spectrometry imaging for drug distribution studies. J Proteomics 2012;75:4999-5013.
66. Reyzer ML, Caprioli RM. MALDI-MS-based imaging of small molecules and proteins in tissues. Curr Opin Chem Biol 2007;11:29-35.
67. Reyzer ML, Hsieh Y, Ng K, et al. Direct analysis of drug candidates in tissue by matrix-assisted laser desorption/ionization mass spectrometry. J Mass Spectrom 2003;38:1081-1092.
68. Atkinson SJ, Loadman PM, Sutton C, et al. Examination of the distribution of the bioreductive drug AQ4N and its active metabolite AQ4 in solid tumours by imaging matrix-assisted laser desorption/ ionisation mass spectrometry. Rapid Commun Mass Spectrom 2007; 21:1271-1276.
69. Drexler DM, Garrett TJ, Cantone JL, et al. Utility of imaging mass spectrometry (IMS) by matrix-assisted laser desorption ionization (MALDI) on an ion trap mass spectrometer in the analysis of drugs and metabolites in biological tissues. J Pharmacol Toxicol Methods 2007; 55:279-288.
70. Signor L, Varesio E, Staack RF, et al. Analysis of erlotinib and its metabolites in rat tissue sections by MALDI quadrupole time-of-flight mass spectrometry. J Mass Spectrom 2007;42:900-909.
71. Khatib-Shahidi S, Andersson M, Herman JL, et al. Direct molecular analysis of whole-body animal tissue sections by imaging MALDI mass spectrometry. Anal Chem 2006;78:6448-6456.
72. Reyzer ML, Chaurand P, Angel PM, et al. Direct molecular analysis of whole-body animal tissue sections by MALDI imaging mass spectrometry. Methods Mol Biol 2010;656:285-301.
73. Rohner TC, Staab D, Stoeckli M. MALDI mass spectrometric imaging of biological tissue sections. Mech Ageing Dev 2005;126:177-185.
74. Sugiura Y, Setou M. Imaging mass spectrometry for visualization of drug and endogenous metabolite distribution: toward in situ pharmacometabolomes. J Neuroimmune Pharmacol 2010;5:31-43.
75. Prideaux B, Staab D, Stoeckli M. Applications of MALDI-MSI to pharmaceutical research. Methods Mol Biol 2010;656:405-413.
76. Marko-Varga G, Fehniger TE, Rezeli M, et al. Drug localization in different lung cancer phenotypes by MALDI mass spectrometry imaging. J Proteomics 2011;74:982-992.
77. Sun N, Walch A. Qualitative and quantitative mass spectrometry imaging of drugs and metabolites in tissue at therapeutic levels. Histochem Cell Biol 2013;140:93-104.
78. Greer T, Sturm R, Li L. Mass spectrometry imaging for drugs and metabolites. J Proteomics 2011;74:2617-2631.
79. Castellino S, Groseclose MR, Wagner D. MALDI imaging mass spectrometry: bridging biology and chemistry in drug development. Bioanalysis 2011;3:2427-2441.
80. Lietz CB, Gemperline E, Li L. Qualitative and quantitative mass spectrometry imaging of drugs and metabolites. Adv Drug Deliv Rev 2013;65:1074-1085.
81. Huber K, Feuchtinger A, Borgmann D, et al. A novel approach of MALDI drug imaging, immunohistochemistry, and digital image analysis for drug distribution studies in tissues. Anal Chem 2014;86: 10568-10575.
82. Balluff B, Rauser S, Meding S, et al. MALDI imaging identifies prognostic seven-protein signature of novel tissue markers in intestinal-type gastric cancer. Am J Pathol 2011;179:2720-2729.
83. Bauer JA, Chakravarthy AB, Rosenbluth JM, et al. Identification of markers of taxane sensitivity using proteomic and genomic analyses of breast tumors from patients receiving neoadjuvant paclitaxel and radiation. Clin Cancer Res 2010;16:681-690.
84. Schwamborn K, Krieg RC, Jirak P, et al. Application of MALDI imaging for the diagnosis of classical Hodgkin lymphoma. J Cancer Res Clin Oncol 2010;136:1651-1655.
85. Pavlidis N, Fizazi K. Cancer of unknown primary (CUP). Crit Rev Oncol Hematol 2005;54:243-250.
86. Pavlidis N, Pentheroudakis G. Cancer of unknown primary site. Lancet 2012;379:1428-1435.
87. Bugat R, Bataillard A, Lesimple T, et al. Summary of the Standards, Options and Recommendations for the management of patients with carcinoma of unknown primary site (2002). Br J Cancer 2003;89(Suppl 1): S59-S66.
88. Meding S, Nitsche U, Balluff B, et al. Tumor classification of six common cancer types based on proteomic profiling by MALDI imaging. J Proteome Res 2012;11:1996-2003.
89. Balluff B, Elsner M, Kowarsch A, et al. Classification of HER2/neu status in gastric cancer using a breast-cancer derived proteome classifier. J Proteome Res 2010;9:6317-6322.
90. Rauser S, Marquardt C, Balluff B, et al. Classification of HER2 receptor status in breast cancer tissues by MALDI imaging mass spectrometry. J Proteome Res 2010;9:1854-1863.
91. Casadonte R, Kriegsmann M, Zweynert F, et al. Imaging mass spectrometry to discriminate breast from pancreatic cancer metastasis in formalin-fixed paraffin-embedded tissues. Proteomics 2014;14:956-964.
92. Lazova R, Seeley EH, Keenan M, et al. Imaging mass spectrometry-a new and promising method to differentiate Spitz nevi from Spitzoid malignant melanomas. Am J Dermatopathol 2012;34:82-90.
93. M'Koma AE, Seeley EH, Washington MK, et al. Proteomic profiling of mucosal and submucosal colonic tissues yields protein signatures that differentiate the inflammatory colitides. Inflamm Bowel Dis 2011;17:875-883.
94. Dalerba P, Kalisky T, Sahoo D, et al. Single-cell dissection of transcriptional heterogeneity in human colon tumors. Nat Biotechnol 2011;29:1120-1127.
95. Gerlinger M, Rowan AJ, Horswell S, et al. Intratumor heterogeneity and branched evolution revealed by multiregion sequencing. N Engl J Med 2012;366:883-892.
96. Maley CC, Galipeau PC, Finley JC, et al. Genetic clonal diversity predicts progression to esophageal adenocarcinoma. Nat Genet 2006;38:468-473.
97. Wu JM, Halushka MK, Argani P. Intratumoral heterogeneity of HER-2 gene amplification and protein overexpression in breast cancer. Hum Pathol 2010;41:914-917.
98. Greaves M, Maley CC. Clonal evolution in cancer. Nature 2012;481: 306-313.
99. Turner NC, Reis-Filho JS. Genetic heterogeneity and cancer drug resistance. Lancet Oncol 2012;13:e178-e185.
100. Willems SM, van Remoortere A, van Zeijl R, et al. Imaging mass spectrometry of myxoid sarcomas identifies proteins and lipids specific to tumour type and grade, and reveals biochemical intratumour heterogeneity. J Pathol 2010;222:400-409.
101. Jones EA, van Remoortere A, van Zeijl RJ, et al. Multiple statistical analysis techniques corroborate intratumor heterogeneity in imaging mass spectrometry datasets of myxofibrosarcoma. PLoS One 2011;6:e24913.
102. Balluff B, Frese CK, Maier SK, et al. De novo discovery of phenotypic intra-tumor heterogeneity using imaging mass spectrometry. J Pathol 2014;235:3-13.
103. Bessede E, Angla-Gre M, Delagarde Y, et al. Matrix-assisted laser-desorption/ionization biotyper: experience in the routine of a University hospital. Clin Microbiol Infect 2011;17:533-538.
104. Dhiman N, Hall L, Wohlfiel SL, et al. Performance and cost analysis of matrix-assisted laser desorption ionization-time of flight mass spectrometry for routine identification of yeast. J Clin Microbiol 2011; 49:1614-1616.
105. Berman DM, Bosenberg MW, Orwant RL, et al. Investigative pathology: leading the post-genomic revolution. Lab Invest 2012; 92:4-8.
106. Buck A, Halbritter S, Spath C, et al. Distribution and quantification of irinotecan and its active metabolite SN-38 in colon cancer murine model systems using MALDI MSI. Anal Bioanal Chem 2015; e-pub ahead of print.